TABLE 2.

Summary of the Safety Profiles of GLP-1 Receptor Agonists and SGLT2 Inhibitors

Type of AE	GLP-1 Receptor Agonists	SGLT2 Inhibitors
Most common AEs	Mild or moderate gastrointestinal disorders (higher incidence with exenatide BID than exenatide QW) (28,71–76), injection site nodules (76)	Female genital mycotic infections (37–40), urinary tract infections (37–39)
AEs of special interest	Thyroid C-cell tumors: boxed warning in prescribing information. Based on animal studies, these agents are contraindicated in patients with a personal or family history of medullary thyroid carcinoma or MEN-2 syndrome (28,73–76)	Lower-extremity amputations: boxed warning in prescribing information for canagliflozin (38); included in warnings and precautions for ertugliflozin (40)
	Acute pancreatitis: included in warnings and precautions in prescribing information (28,71–76)	Fractures: included in the warnings and precautions in prescribing information for canagliflozin (38)
		Diabetic ketoacidosis: included in the warnings and precautions in prescribing information (37–40)
		Events consistent with volume depletion: may occur as SGLT2 inhibitors cause intravascular volume contraction (37–40)
		Acute kidney injury: included in warnings and precautions in prescribing information (37–40). No warnings or precautions for pancreatitis, malignancies, or thromboembolic events in prescribing information (37–40)

BID, twice daily; MEN-2, multiple endocrine neoplasia.